Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018)

Savara (SVRA) reported Asset Writedowns and Impairment of $21.7 million for Q1 2018, up 21037.15% on a QoQ basis from $102625.0 in Q4 2012.

Savara (SVRA) has 2 years of Asset Writedowns and Impairment data on file, last reported at $21.7 million in Q1 2018.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $21.7 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $21.7 million (changed N/A YoY) and the FY2018 annual result came in at $21.7 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment improved to $21.7 million in Q1 2018 per SVRA's latest filing, from $102625.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $21.7 million in Q1 2018 and bottomed at $21.7 million in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Savara 1.30 Bn 1.30 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2018 21.69 Mn
Mar 31, 2018 21.69 Mn
Dec 31, 2012 102,625.00
Dec 31, 2012 102,625.00